Protagen AG
Otto Hahn Str. 15
Dortmund
44227
Germany
Tel: 49-231-9742-890
Fax: 49-231-9742-891
Website: http://www.protagen.de/
Email: info@protagen.de
46 articles about Protagen AG
-
Protagen AG Appoints Immuno-Oncology Experts to Its Scientific Advisory Board
12/18/2018
Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, Heidelberg, Germany) and Dr. Aurélien Marabelle (Gustave Roussy, Paris, France)
-
The National Center for Tumor Diseases (NCT) Heidelberg and Protagen AG Extend Their Collaboration to Investigate the Immuno-Competence of Urothelial Cancer Patients Receiving Immunotherapy
10/18/2018
In recent years, checkpoint inhibitors have changed treatment paradigms in cancer.
-
NEC Laboratories Europe GmbH, the National Center for Tumor Diseases and Protagen AG Collaborate to Improve Information Integration and Artificial Intelligence for Better Therapy Decisions in Immuno-Oncology
9/26/2018
Protagen AG, the National Center for Tumor Diseases (NCT) and NEC Laboratories Europe GmbH have today announced a collaboration to improve the in silico prediction of immunotherapy response in malignant melanoma.
-
Gustave Roussy and Protagen AG Collaborate to Improve the Risk Profiling of Cancer Patients Undergoing Immunotherapy
4/10/2018
Protagen AG and Gustave Roussy have today announced the start of a collaboration to utilize Protagen’s SeroTag® technology to help identify biomarkers that predict and monitor immune-related adverse events (irAEs) in cancer patients treated with checkpoint inhibitors.
-
Protagen AG Join Forces With The U.S. National Cancer Institute To Answer Pressing Questions In Immuno-Oncology
2/2/2017
-
Protagen AG Release: The German National Center For Tumor Diseases (NCT) Heidelberg And Company Investigate Responsiveness To Checkpoint Inhibitors In Melanoma
1/17/2017
-
Protagen AG Successfully Joined Forces With Novartis AG To Support Clinical Development Of A Novel Compound In An Autoimmune Indication
12/20/2016
-
Protagen AG Launches NavigAID Assay To Support Clinical Drug Development For Autoimmune Diseases
12/14/2016
-
Protagen AG Launches Navigaid Assay To Support Clinical Drug Development For Autoimmune Diseases
12/13/2016
-
Protagen AG Inks License Agreement With INOVA Diagnostics For Its Proprietary BICD2 Biomarker
8/11/2016
-
Protagen AG Appoints Bernhard Kirschbaum As New Chairman And Oliver Schacht As New Board Member
7/20/2016
-
Protagen AG Announces CE Mark For Its Proprietary Multilisa® BICD2 Test For Better Diagnosis Of Systemic Sclerosis
6/15/2016
-
Protagen AG Launches First CE Marked Diagnostic Assays Multilisa® CENP-B And Scl-70 For The Diagnosis Of Systemic Sclerosis
5/31/2016
-
Protagen AG Supports Novel Route To Serum Based Prostate Cancer Diagnostics
2/11/2016
-
Protagen AG Joins RA-MAP Consortium To Support Identification Of Predictors Of Remission In Rheumatoid Arthritis (RA)
1/21/2016
-
Protagen AG Establishes Scientific Advisory Board
12/10/2015
-
Protagen AG Joins MATURA Consortium To Support Identification Of Treatment Response Predictors In Rheumatoid Arthritis (RA)
12/1/2015
-
Protagen AG Launches Multilisa BICD2 Offering New Options In Diagnosing Systemic Sclerosis (Ssc)
11/16/2015
-
Protagen AG And Mikrogen Agree On Co-Development Of Novel Lyme Disease Markers
11/12/2015
-
Protagen AG Appoints New Board Members To Expand Expertise In Diagnostics Commercialization
10/1/2015